Avenge Bio

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

Avenger Bio Insecticide

DelveInsight Business Research LLP on LinkedIn: Pharma News Updates for AbbVie, Novartis, Avenge Bio, Eli Lilly

Avenge Bio completes first dose cohort in AVB-001 Phase I/II trial

Bio Tech Nutra Avenger - Stack3d Database

MartialArts Reigns (on WEBCOMICS, link in bio, C.0.D.E of Starter Perk

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

Healthcare Weekly Pulse Check Issue #1 Jan.1-Jan.7, 2022

Commercialization Highlights, Office of Technology Transfer, Office of Research

Avenge Bio Receives FDA Fast Track Designation for AVB-001, a Novel Cell Therapy Leveraging the LOCOcyte™ Immunotherapy Platform